Read now

CNS-ICNA 2020

Discover the conference highlights

Skin α-synuclein aggregation in Parkinson’s disease

Takeaway

  • Skin pathological α-synuclein (αSynP) seeding activity may serve as a novel biomarker for antemortem diagnosis of Parkinson’s disease (PD) and other synucleinopathies.

Why this matters

  • Brain deposition of (αSynP) is a hallmark feature of synucleinopathies including PD, Lewy body dementia (LBD) and multiple system atrophy (MSA), but whether skin-based αSynP aggregation is detectable in these disorders is unknown.

  • Identification of an early, less invasive and more cost-effective biomarker test for people at high risk of developing synucleinopathies may have implications for early initiation of treatment, thus improving patient longevity and quality of life.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.